The Eisai pharmaceutical laboratory announced on Monday 1 July the launch of a "therapeutic trial" of a medication with Down syndrome patients aged 15 to 39. The treatment being tested is a cholinesterase inhibitor called "Aricept". It is normally used to treat certain symptoms of Alzheimer’s disease, "based on the hypothesis of a cerebral deficit in acetylcholine in some patients and on scientific research which shows that donepezil improves certain brain functions of patients."
The programme will initially involve 10 hospitals around Japan and dozens of patients aged 15 to 39. It is due to last four years.